Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 271Lymphoid 229Other hematologic neoplasm 201Myeloid 106CNS 59Sarcoma 46Classical hematology 38Dermatologic 36Gastrointestinal 18Other solid neoplasm 16Breast 14Genitourinary 13Gynecologic 12Other neoplasm 5Other 2Endocrine 2Thoracic 1

Conditions

Thymoma 1Myelodysplastic Syndromes 1Leukemia 1Graft vs Host Disease 1Anemia, Refractory 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melphalan × Thoracic × Clear all
NCT00003662 2011-03-07

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Roswell Park Cancer Institute

Phase 2 Completed
90 enrolled
Classical hematologyMyeloidOther hematologic neoplasmThoracic

Anemia, Refractory, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡